The short answer
Melatonin may add to fluphenazine-related sleepiness. The exact clinical risk is not quantified, and laboratory or animal studies do not establish a safe dose or timing plan.
What this answer covers
Oral fluphenazine with the exact supplement preparation described.
- Supplement or preparation
- Melatonin
- Medication ingredient
- fluphenazine
Both products can affect alertness
Fluphenazine can cause drowsiness. Melatonin can also make people sleepy, with longer-lasting daytime effects possible in some older adults. This supports discussing the actual product and dose.
Sleepiness and measured performance are different
A small placebo-controlled study of afternoon melatonin found greater subjective sleepiness after a prolonged task, but no overall adverse effect on its objective driving-test battery. This does not mean every dose causes measurable impairment.
The animal finding went in different directions
In injected-dose rat experiments, melatonin reduced fluphenazine-associated motor immobility in one light phase but increased it in another. Motor behavior under those conditions is not a human sedation outcome and does not provide an oral timing recommendation.
Review the actual products
Bring the supplement label and your full medication list to the pharmacist, especially if fluphenazine already affects alertness. Avoid driving when sleepy or impaired. No supplement dose or short spacing interval has been established to prevent overlapping effects.
Evidence and practical considerations
Side effects & toxicity
Melatonin may add to fluphenazine-related sleepiness. The exact clinical risk is not quantified, and laboratory or animal studies do not establish a safe dose or timing plan.
- Exact scope
- Oral fluphenazine with the exact supplement preparation described. with Oral fluphenazine with the stated label and formulation limits.
- Medication form and route
- oral
What remains uncertain
- Conditional alertness review, with the standalone objective-performance null finding retained. Animal and laboratory results do not establish human pharmacokinetics or an adverse-event rate. Experimental light-phase differences do not provide a patient dosing rule.
Factors that may matter: Exact preparation and amount; Other medicines; Seizure history, alertness or electrolyte status where relevant.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral fluphenazine.
May cause drowsiness or lethargy. Hypotension is not usually a problem but can occur. Atropine and similar agents may potentiate anticholinergic activity. Caution with seizure history.
How this applies: Exact ingredient and oral-route clinical context.
Label class warnings do not establish every exact botanical interaction, event rate or protective supplement interval.
Source 2: Federal supplement guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the named botanical or supplement.
Sleepiness is a possible effect. Older people may have prolonged daytime drowsiness; commercial products and long-term safety data vary.
How this applies: Supports conditional alertness review without claiming every dose objectively impairs performance.
General guidance does not quantify this exact medication combination or establish a universal protective interval.
Source 3: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Twenty healthy adults in a crossover.
Subjective sleepiness increased after a prolonged task, but the overall objective driving-test battery did not show impairment.
How this applies: Supports nuance between sleepiness and measured performance.
Small single-dose study without the target antipsychotic. Subjective sleepiness and objective performance are different outcomes.
Source 4: Original animal study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Rats tested under light and dark phase conditions.
Melatonin reduced fluphenazine-associated hypokinesia in one light phase but increased it in the dark phase.
How this applies: Retains bidirectional animal results instead of assuming uniform added sleepiness.
Motor immobility is not a human sedation score; high injected doses and circadian conditions do not establish oral dose scheduling.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked draft with exact preparation limits, original study findings and uncertainty. Clinical review not recorded. | |
| Research summary published |
Article revision: 2e2e09f08cb04d67
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.